The COVID-19 pandemic has caused mayhem globally since the beginning of 2020. Owing to the immune dysfunction inherent to cirrhosis and the poor general condition, patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19. Recently, a number of vaccines against SARS-Cov-2 have been approved for emergency use around the globe. Although the phase 2/3 trials of these vaccines show them to be safe and effective in the general population, data in patients with CLD are scarce. The number of patients with CLD enrolled on these trials is small, and no liver-related adverse effects have been reported yet. Various liver societies have come up with guidelines on vaccination in this population and recommend vaccination on a priority basis. Trials to assess the safety and efficacy of the COVID vaccines are underway and are likely to provide valuable insight into this matter.
For more information, please visit https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214314/
Reference: Anand Sharma, Itish Patnaik, Ashok Kumar, and Rohit Gupta. COVID-19 Vaccines in Patients With Chronic Liver Disease. J Clin Exp Hepatol. 2021 Nov-Dec; 11(6): 720–726.
Disclaimer: The information provided on this website is for informational purposes only and is not intended to take the place of consultation with your physician.